Drug firm Dr Reddy's Laboratories on Monday disclosed that it has launched in the US generic Paricalcitol injection, which will be used for treatment related with chronic kidney disease. It has launched the injection USP , having the strengths of 2 mcg, 5 mcg and 10 mcg, as per Dr Reddy's Laboratories’ filing . The product of the company is generic version of AbbVie Inc's Zemplar injections, it further added. The injection is first abbreviated new drug application (ANDA) product, launched in the US after the approval from the US Food and Drug Administration, it mentioned . Zemplar is used for the prevention and treatment of secondary hyperparathyroidism related with chronic renal failure. Dr Reddy’s mentioned that the Zemplar brand and generic had US sales of around $22.5 million MAT for the most latest 12 months ending July 2016 as per IMS Health.
Dr Reddys share price closed below 0.07%. The stock opened at Rs. 3170.00 as compared to its previous closing at Rs. 3157.35. The stock touched the days high and low at Rs. 3200 and Rs. 3154.45. Approximately 2,78,985 shares were traded in the counter with a traded value of Rs. 8,853.95 lacs, as per NSE.
The 52 week high of Dr Reddys share price is observed at Rs. 4,386.60
The 52 week high of Dr Reddys share price is observed at Rs. 4,386.60
on 20th Oct ‘15 while the 52 week low is seen at Rs. 2,750.05 on 21st Jan ‘16. The closest support and resistance level of the stock for this day stands at Rs. 3115.50 and Rs. 3225.00. The stock was quoting at Rs. 3155.25. Dr Reddys is among the top 500performing stocks for this quarter, analyzed by Dynamic Levels research analyst for this quarter.
In order to acquire further details on the support and resistance refer to Dr Reddys share price forecast.
No comments:
Post a Comment